3 Asian Growth Companies With High Insider Ownership Growing Earnings At 28%
In recent weeks, the Asian markets have experienced volatility amid global concerns over AI spending and inflation pressures, impacting investor sentiment across various sectors. Despite these challenges, growth companies with high insider ownership can offer potential resilience and alignment of interests between management and shareholders.
Top 10 Growth Companies With High Insider Ownership In Asia
| Name | Insider Ownership | Earnings Growth |
| Seojin SystemLtd (KOSDAQ:A178320) | 18% | 106.6% |
| Meitu (SEHK:1357) | 23.1% | 26.7% |
| Jiangxi Fushine Pharmaceutical (SZSE:300497) | 21.1% | 50.8% |
| JHT DesignLtd (SHSE:603061) | 23.1% | 48.6% |
| HUMAN MADE (TSE:456A) | 29.1% | 28.7% |
| Guangdong Shenling Environmental Systems (SZSE:301018) | 36.7% | 65.4% |
| Great Microwave Technology (SHSE:688270) | 21.1% | 95.2% |
| Gpixel Changchun Microelectronics (SEHK:3277) | 18.2% | 32% |
| Fulin Precision (SZSE:300432) | 11.7% | 66.5% |
| Biocytogen Pharmaceuticals (Beijing) (SEHK:2315) | 14.1% | 39.2% |
Below we spotlight a couple of our favorites from our exclusive screener.
Eyebright Medical Technology (Beijing) (SHSE:688050)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Eyebright Medical Technology (Beijing) Co., Ltd. operates in the medical technology sector and has a market capitalization of CN¥8.11 billion.
Operations: The company's revenue is primarily derived from its medical products segment, which generated CN¥1.63 billion.
Insider Ownership: 17.7%
Earnings Growth Forecast: 29.0% p.a.
Eyebright Medical Technology (Beijing) is forecasted to achieve significant annual earnings growth of 28.95%, surpassing the CN market's 26.4%. Despite trading at 36.8% below its estimated fair value, recent performance shows a drop in profit margins from 26.1% to 14.6%, and a decline in net income for H1 2026 compared to last year. The company was recently removed from the FTSE All-World Index, reflecting potential challenges ahead despite strong insider ownership.
- Click here and access our complete growth analysis report to understand the dynamics of Eyebright Medical Technology (Beijing).
- Our valuation report here indicates Eyebright Medical Technology (Beijing) may be undervalued.
Kinco Automation (Shanghai)Ltd (SHSE:688160)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Kinco Automation (Shanghai) Co., Ltd specializes in developing, producing, and selling components for motion control and human-machine interaction in China with a market cap of CN¥8.43 billion.
Operations: Kinco Automation (Shanghai) Co., Ltd generates revenue through its development, production, and sale of components focused on motion control and human-machine interaction within the Chinese market.
Insider Ownership: 14.0%
Earnings Growth Forecast: 28.2% p.a.
Kinco Automation (Shanghai) Ltd. is experiencing robust growth, with earnings forecasted to rise significantly at 28.24% annually, outpacing the broader CN market's 26.4%. Recent reports show a substantial increase in sales to CNY 447.69 million for H1 2026 from CNY 310.9 million last year, alongside net income growth to CNY 36.33 million from CNY 26.11 million previously. However, its share price has been highly volatile recently and future Return on Equity is expected to be low at 9.8%.
- Click here to discover the nuances of Kinco Automation (Shanghai)Ltd with our detailed analytical future growth report.
- Upon reviewing our latest valuation report, Kinco Automation (Shanghai)Ltd's share price might be too optimistic.
Ningbo Zhenyu Technology (SZSE:300953)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Ningbo Zhenyu Technology Co., Ltd. specializes in the research, design, production, and sale of precision progressive stamping dies and structural parts both in China and internationally, with a market cap of CN¥20.42 billion.
Operations: The company's revenue from Machinery & Industrial Equipment amounts to CN¥12.08 billion.
Insider Ownership: 37.7%
Earnings Growth Forecast: 52.7% p.a.
Ningbo Zhenyu Technology is set for substantial growth, with earnings projected to increase by 52.7% annually, surpassing the CN market's 26.4%. Revenue is expected to grow at 24.8% per year, outpacing the market average of 16.2%. Recent results show significant improvement, with sales reaching CNY 5.36 billion and net income doubling to CNY 423.32 million for H1 2026 compared to last year, although debt coverage remains a concern due to insufficient operating cash flow.
- Unlock comprehensive insights into our analysis of Ningbo Zhenyu Technology stock in this growth report.
- Our valuation report unveils the possibility Ningbo Zhenyu Technology's shares may be trading at a discount.
Seize The Opportunity
- Gain an insight into the universe of 514 Fast Growing Asian Companies With High Insider Ownership by clicking here.
- Contemplating Other Strategies? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com